Selumetinib sulfate/MK-2206

N/A

Report date: 2023/06/02 18:01:49

Base Information

Drug NameSelumetinib sulfate/MK-2206
Drug Alias NameSelumetinib Sulfate•MK-2206硫酸舍美替尼•MK-2206硫酸舍美替尼-MK-2206Selumetinib Sulfate-MK-2206Selumetinib Sulfate+MK-2206 +[10] 
ClassificationSmall molecules
Mechanisms of ActionSerine/threonine-protein kinase AKT1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitorsDual specificity mitogen-activated protein kinase kinase 1 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 2Serine/threonine-protein kinase AKT1Dual specificity mitogen-activated protein kinase kinase 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsRectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[8] 
CombinationsYes Selumetinib sulfateMK-2206
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca PlcMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesNational Cancer Institute
Active IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsTriple Negative Breast Neoplasms
Inactive IndicationsRectal NeoplasmsAdenocarcinomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A